A paradigm shift in
cellular-based therapy
for regenerative medicine
Our platform technologies Progenza™ and Sygenus are novel approaches to pain, that leverage stem cells as cellular pharmacies and utilise Secretome as a therapeutic agent.
Regeneus Half Year Results H1 FY21
Regeneus' (ASX:RGS) CEO Karolis Rosickas announces the release of the Company's Half Year Results for the period ending 31 December 2020. Read the full report here and the cover note here.
Regeneus to be granted new patent to target pain in Japan
Regeneus announced it has been granted a key patent for its lead stem cell technology platform Progenza™ for the treatment of pain in Japan. Read the full announcement on the ASX here.
Regeneus Quarterly Report Q2 FY21
Regeneus' (ASX:RGS) CEO Karolis Rosickas announces the release of the Company's Q2 FY21 results. Read Regeneus' Quarterly Cashflow report for the period ending 31 December 2020 here.
Q&A with Sinead Blaber, Director of Clinical Development and Medical Affairs at Regeneus
Q. What is your background and experience in the regenerative medicine and stem cell space? How did this lead you to Regeneus? A. I started my PhD in 2009, investigating the mechanisms of bacterial spore formation with the overall aim to identify new antibiotic targets. My husband worked in the…
Company update and season’s greetings from Regeneus
Regeneus CEO Karolis Rosickas shares a company update as we look ahead to 2021.
The Science
MSCs and Secretome are the next frontier in targeting pain and inflammation. They combine to make a 'bioactive soup' that repurposes inflamed tissue at a site of injury, helping reduce pain and further tissue damage.
Product Pipeline
Our platform technologies Progenza™ and Sygenus represent a potential major paradigm shift in treating pain and inflammation at its source, by harnessing the power of MSCs and Secretome.
IP and Manufacturing
Our manufacturing techniques ensure cost-effective and high batch-to-batch consistency in our stem cell production. Alongside our research partners, we can scale up our platform technologies to meet market demand.
Partnering with us
Regeneus is constantly looking for partners and research collaborators.
Contact us for more information.